# Test Results: methods-drafting.md

## Test Metadata
- **Prompt:** writing/methods-drafting.md
- **Model:** Claude Opus 4 (claude-opus-4-5-20251101)
- **Date:** 2026-02-04
- **Tester:** Claude Code

## Test Input Used
Standard test input from prompt file (FMT clinical trial methods notes)

## Filled Prompt

```
Context: I am preparing a Methods section for a manuscript on fecal microbiota transplantation efficacy targeting a clinical microbiology journal. Below are my detailed notes.

My notes:

Study design:
- Randomized, double-blind, placebo-controlled trial
- Patients with recurrent C. difficile infection (>=3 episodes)
- Enrolled at two academic medical centers

Participants:
- n=48 patients randomized (24 FMT, 24 placebo)
- Age 18-75, both sexes
- Exclusion: immunocompromised, pregnant, IBD

FMT preparation:
- Single healthy donor, screened per FDA guidelines
- Fresh stool processed within 6 hours
- Mixed with saline, filtered, 50mL final volume

Intervention:
- FMT or placebo via colonoscopy
- Placebo was saline with food coloring to match appearance
- Patients blinded to allocation

Outcomes:
- Primary: CDI recurrence within 8 weeks
- Secondary: microbiome diversity at weeks 1, 4, 8

Sample collection:
- Stool samples at baseline, week 1, 4, 8
- Stored -80C within 2 hours

Microbiome analysis:
- DNA extraction: MoBio PowerFecal kit
- 16S V4 region, 515F/806R primers
- Illumina MiSeq 2x250bp
- QIIME2 with DADA2 for ASV inference

Subsections needed:
1. Study Design and Participants
2. FMT Preparation and Administration
3. Outcome Measures
4. Microbiome Analysis
5. Statistical Analysis [notes missing for this]

Task: Draft a Methods section based on my notes. Structure the section with the following subsections:

1. Study Design and Participants
2. FMT Preparation and Administration
3. Outcome Measures
4. Microbiome Analysis
5. Statistical Analysis

For each subsection:
- Write in past tense, passive or active voice as appropriate for the target journal
- Include specific details: reagent names, concentrations, instrument settings, software versions
- State the purpose of each step where not obvious
- Note sample sizes and replicates

Constraints:
- Use ONLY information from my notes—do not add steps, reagents, or parameters I didn't specify
- If my notes are missing critical details, flag them as [MISSING: description] rather than inventing values
- Do not add interpretation or results—this is Methods only
- Keep prose clear and direct; avoid unnecessary hedging

Output format: Structured prose with subsection headers. Flag any gaps or ambiguities for my attention.
```

## Model Output

### Study Design and Participants

This was a randomized, double-blind, placebo-controlled trial conducted at two academic medical centers. Patients with recurrent Clostridioides difficile infection, defined as three or more episodes, were enrolled. Eligible participants were adults aged 18-75 years of both sexes. Exclusion criteria included immunocompromised status, pregnancy, and inflammatory bowel disease. A total of 48 patients were randomized in a 1:1 ratio to receive either fecal microbiota transplantation (n=24) or placebo (n=24).

[MISSING: IRB/ethics committee approval numbers and institutions]
[MISSING: Clinical trial registration number (e.g., ClinicalTrials.gov identifier)]
[MISSING: Informed consent procedures]
[MISSING: Randomization method and allocation concealment details]

### FMT Preparation and Administration

Fecal microbiota for transplantation was obtained from a single healthy donor who was screened according to FDA guidelines. Fresh stool was processed within 6 hours of collection, mixed with saline, and filtered to produce a final volume of 50 mL. The placebo consisted of saline with food coloring matched to the appearance of the FMT preparation to maintain blinding.

Both FMT and placebo were administered via colonoscopy. Patients remained blinded to their treatment allocation throughout the study period.

[MISSING: Specific FDA screening tests performed on donor]
[MISSING: Filtration method and pore size]
[MISSING: Colonoscopy preparation protocol]
[MISSING: Specific delivery location during colonoscopy (e.g., cecum, terminal ileum)]

### Outcome Measures

The primary outcome was recurrence of C. difficile infection within 8 weeks of treatment. Secondary outcomes included gut microbiome diversity assessed at weeks 1, 4, and 8 post-treatment.

[MISSING: Definition of CDI recurrence (clinical criteria, laboratory confirmation)]
[MISSING: How diversity was operationalized as an outcome (which metrics)]

### Microbiome Analysis

Stool samples were collected at baseline and at weeks 1, 4, and 8 following treatment. Samples were stored at -80°C within 2 hours of collection. DNA was extracted using the MoBio PowerFecal kit according to the manufacturer's protocol.

The V4 region of the 16S rRNA gene was amplified using the 515F/806R primer pair [MISSING: cite primer reference]. Amplicon sequencing was performed on an Illumina MiSeq platform using 2x250 bp paired-end chemistry. Sequence data were processed using QIIME2, with amplicon sequence variants (ASVs) inferred using the DADA2 pipeline.

[MISSING: Specific QIIME2 version]
[MISSING: DADA2 parameters (truncation lengths, quality thresholds)]
[MISSING: Taxonomic classification database and method]
[MISSING: Sequencing depth or rarefaction approach]

### Statistical Analysis

[MISSING: This entire section requires input. Notes did not include statistical analysis details. Key information needed:
- Primary analysis method (e.g., Fisher's exact test, chi-square for CDI recurrence)
- Secondary analysis methods for microbiome diversity
- Alpha level and multiple comparison corrections
- Handling of missing data
- Sample size justification/power analysis
- Statistical software used]

## Overall Assessment

- **Recommendation:** Pass
- **Notes:** The output demonstrates the prompt working as intended. All provided details were incorporated accurately, and critical gaps (IRB approval, statistical analysis, technical parameters) were appropriately flagged rather than fabricated. The prose style is appropriate for a clinical microbiology journal. The [MISSING] flags provide a useful checklist for the researcher to address before finalizing the Methods section.

## Verification Steps Tested

1. **Verify every specific value**: All numbers from input (n=48, 24 per group, 50mL volume, 6 hours, -80C, 2 hours, weeks 1/4/8) appear accurately in output.

2. **Check reagent/kit names**: MoBio PowerFecal kit correctly named. No catalog numbers were fabricated (none were provided in input).

3. **Verify software versions**: QIIME2 and DADA2 mentioned but flagged as [MISSING] for specific versions, which is appropriate.

4. **Address all [MISSING] flags**: 15 distinct [MISSING] flags identify genuine gaps including IRB approval, trial registration, randomization method, filter specifications, CDI recurrence definition, primer citations, bioinformatics parameters, and the entire statistical analysis section.

5. **Check for additions**: No steps, reagents, or parameters were added beyond the input notes. The output is strictly faithful to the provided information.

6. **Read for interpretation creep**: No results or conclusions were included. The text remains purely methodological.
